Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans.
Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans.
复制标题
淀粉样蛋白显像剂 11C-PIB 在人体中的生物分布和辐射剂量测定。
作者：
N. Scheinin;T. Tolvanen;I. Wilson;E. Arponen;K. Någren;J. Rinne
无标签
我们研究了 PET 淀粉样蛋白显像剂 (11)C-PIB ((11)C-6-OH-BTA-1)（其中 BTA 是苯并噻唑）在人体中的生物分布和辐射剂量测定。以前的辐射暴露估计是基于动物实验。人体剂量测定研究对于 (11)C-PIB PET 研究的风险效益平衡评估至关重要。
方法
我们使用健康志愿者 16 次不同 (11)C-PIB PET 扫描的数据来估计辐射暴露。其中 6 次扫描是腹部区域的动态成像：3 次覆盖上腹部，3 次覆盖中腹部。平均而言，静脉注射 489 MBq 的 (11)C-PIB（范围为 416-606 MBq），记录动态发射扫描长达 40 分钟。两名受试者对整个身体进行了全身成像以说明生物分布。还分析了我们之前的 (11)C-PIB 研究中的 PET 脑扫描以及血液和尿液放射性测量结果。研究了十三个源器官和身体的其余部分，以估计停留时间和平均辐射吸收剂量。 MIRD方法用于计算选定目标器官和整个身体的辐射暴露。
结果
我们的人类数据与之前基于狒狒的生物分布信息之间存在高度的一致性。在我们的研究中，吸收辐射剂量最高的是胆囊壁（41.5微Gy/MBq）、肝脏（19.0微Gy/MBq）、膀胱壁（16.6微Gy/MBq）、肾脏（12.6微Gy/MBq）和大肠上部壁（9.0微Gy/MBq）。肝胆和肾脏系统是清除和排泄的主要途径，大约20%的注射放射性物质被排泄到尿液中。有效辐射剂量为4.74微Sv/MBq。
结论
3维PET淀粉样蛋白成像所需的(11)C-PIB的既定临床剂量具有可接受的有效辐射剂量。该剂量与其他 PET 脑受体示踪剂研究中预期的平均暴露剂量相当。 (11)C-PIB 被迅速从体内清除，主要是通过肾脏。从辐射安全的角度来看，这些结果支持(11)C-PIB在临床PET研究中的使用。
UNLABELLED
We investigated the biodistribution and radiation dosimetry of the PET amyloid imaging agent (11)C-PIB ((11)C-6-OH-BTA-1) (where BTA is benzothiazole) in humans. Previous radiation exposure estimates have been based on animal experiments. A dosimetry study in humans is essential for a balanced risk-benefit assessment of (11)C-PIB PET studies.
METHODS
We used data from 16 different (11)C-PIB PET scans on healthy volunteers to estimate radiation exposure. Six of these scans were dynamic imaging over the abdominal region: 3 covering the upper abdomen and 3 covering the middle abdomen. On average, 489 MBq of (11)C-PIB (range, 416-606 MBq) were injected intravenously, and dynamic emission scans were recorded for up to 40 min. Two subjects had whole-body imaging over the entire body to illustrate the biodistribution. PET brain scans and blood and urine radioactivity measurements from our previous (11)C-PIB studies were also analyzed. Thirteen source organs and the remainder of the body were studied to estimate residence times and mean radiation-absorbed doses. The MIRD method was used to calculate the radiation exposure of selected target organs and the body as a whole.
RESULTS
There is a high degree of consistency between our human data and previous biodistribution information based on baboons. In our study, the highest radiation-absorbed doses were received by the gallbladder wall (41.5 microGy/MBq), liver (19.0 microGy/MBq), urinary bladder wall (16.6 microGy/MBq), kidneys (12.6 microGy/MBq), and upper large intestine wall (9.0 microGy/MBq). The hepatobiliary and renal systems were the major routes of clearance and excretion, with approximately 20% of the injected radioactivity being excreted into urine. The effective radiation dose was 4.74 microSv/MBq.
CONCLUSION
The established clinical dose of (11)C-PIB required for 3-dimensional PET amyloid imaging has an acceptable effective radiation dose. This dose is comparable with the average exposure expected in other PET brain receptor tracer studies. (11)C-PIB is rapidly cleared from the body, largely by the kidneys. From the viewpoint of radiation safety, these results support the use of (11)C-PIB in clinical PET studies.
DOI：
--
发表时间：
1997-10
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
M. Graham;L. Peterson;J. Link;M. L. Evans;J. Rasey;W. Koh;J. Caldwell;K. Krohn
通讯作者：
M. Graham;L. Peterson;J. Link;M. L. Evans;J. Rasey;W. Koh;J. Caldwell;K. Krohn